Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04587687 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Joseph Tuscano to University of California, Davis
    • Primary completion date: Dec 2026 to Dec 2027
    • Study completion date: Dec 2026 to May 2028
    • Site contact updated
    v7
  2. Primary completion date: Dec 2024 to Dec 2026
    • Study completion date: May 2025 to Dec 2026
    v6
  3. Primary completion date: Dec 1, 2023 to Dec 2024
    • Study completion date: May 1, 2024 to May 2025
    v5
  4. Primary completion date: Nov 1, 2022 to Dec 1, 2023
    • Study completion date: May 1, 2023 to May 1, 2024
    v4
  5. Re-verified, no change to tracked fieldsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2020 to Dec 4, 2020
    • Site details revised
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial investigates how well brentuximab vedotin and bendamustine work in treating patients with follicular lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Chemotherapy drugs, such as bendamustine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial is being done to determine if the combination of brentuximab vedotin plus bendamustine is safe and to determine the effectiveness of the combination.
Trial Details
NCT Number NCT04587687
Lead Sponsor University of California, Davis
Collaborators: National Cancer Institute (NCI), Seagen Inc.
Conditions
(from sponsor)		 Recurrent Follicular Lymphoma, Refractory Follicular Lymphoma
Related terms Lymphoma, Follicular
Enrollment 23 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov